rethinkPeptides Search
Menu
Study breakdown

Safe Method to Create Diabetic Monkey Models Using Single Dose of Standard-Grade STZ

AnimalLow evidence
The takeaway

A single 100 mg/kg dose of analytical-grade streptozotocin safely induced complete diabetes in cynomolgus monkeys without liver or kidney damage.

3/3 complete diabetes

All three monkeys achieved complete diabetes with no adverse organ effects from a single STZ dose

What the researchers found

Single 100 mg/kg dose of analytical-grade STZ induced complete diabetes in cynomolgus monkeys with destroyed beta cells and <0.5 ng/mL stimulated C-peptide, without organ toxicity.

Why it matters

Primate diabetes models are essential for testing islet transplants and peptide-based diabetes drugs. This accessible method removes the barrier of needing expensive clinical-grade STZ.

The numbers in context

100 mg/kg STZ IV; C-peptide <0.5 ng/mL; triphasic blood glucose response; no vomiting or organ toxicity

How the study worked

3 cynomolgus monkeys received IV STZ (100 mg/kg over 5 min). Blood glucose monitored hourly for 48h then twice daily. C-peptide by ELISA; liver/renal function blood chemistry; islet immunohistochemistry for insulin and glucagon.

Who was studied

3 cynomolgus monkeys

What this study cannot tell us

Only 3 animals — very small sample; no long-term follow-up reported; single STZ source tested; model represents type 1 (beta cell destruction), not type 2 diabetes.

How to read the evidence

Low — proof-of-concept with only 3 animals and no control group; adequate for method validation but limited for generalization.

When this study was published

Published in 2020; STZ diabetic models remain standard in primate diabetes research.

The bigger picture

Better primate diabetes models accelerate development of diabetes therapies including GLP-1 agonists, insulin analogs, and islet transplantation approaches.

Questions still open

  • Is this method reproducible across different batches of analytical-grade STZ?
  • How long does the diabetes model remain stable for long-term drug studies?
  • Would lower doses achieve partial beta cell destruction for a type 2-like model?

Common questions

Why use monkeys for diabetes research?
Monkey physiology is much closer to humans than rodents, making primate models more predictive for testing diabetes drugs and islet transplantation before human trials.
What does streptozotocin do?
STZ selectively destroys insulin-producing beta cells in the pancreas, creating a model of diabetes that closely mimics type 1 diabetes for research purposes.

Read the original research

Induction of diabetes in cynomolgus monkey with one shot of analytical grade streptozotocin.

Animal models and experimental medicine, 3(1), 79-86

Citation

Liu, Zhengzhao; Lu, Ying; Hu, Wenbao; Hara, Hidetaka; Dai, Yifan; Cai, Zhiming; Mou, Lisha. (2020). Induction of diabetes in cynomolgus monkey with one shot of analytical grade streptozotocin.. Animal models and experimental medicine, 3(1), 79-86. https://doi.org/10.1002/ame2.12109